Intermittent Pneumatic Compression Devices Market By Product Type (Portable IPC Devices, Non-portable IPC Devices); By Application (DVT Prevention, Lymphedema Management, Chronic Venous Insufficiency and Varicose-Vein-Related Applications, Sports and Rehabilitation); By End User (Hospitals & Clinics, Homecare Settings, Ambulatory Surgical Centers, Sports Rehabilitation Centers); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Segment Revenue Estimation, Forecast, 2026–2032

Intermittent Pneumatic Compression Devices Market Overview and Growth Analysis

The Global Intermittent Pneumatic Compression (IPC) Devices Market is growing at a CAGR of 6.8%, valued at USD 4.1 billion in 2025 and expected to reach USD 6.1 billion by 2032.

 

The market is supported by two distinct healthcare demand pools: hospital-based mechanical prevention of venous thromboembolism (VTE) and recurring compression therapy for lymphedema and selected chronic venous conditions. Hospital demand is linked to surgery, immobility, trauma, cancer care, and other situations where patients face an elevated risk of deep vein thrombosis (DVT) or pulmonary embolism (PE). Home-care demand comes from patients requiring longer-term management of lymphatic swelling, venous insufficiency, and persistent venous ulcers. These settings create different revenue models, with hospitals purchasing pumps, controllers, and garments for repeated patient episodes, while home therapy is influenced more heavily by prescriptions, payer authorization, DME supply, and recurring patient management.

 

The underlying clinical burden keeps IPC relevant across both settings. The CDC estimates that up to 900,000 people in the United States are affected by VTE annually, with an estimated 60,000–100,000 deaths each year. Recent U.S. estimates also place the lymphedema population at approximately 8–10 million people. Commercial use is increasingly measurable: Tactile Medical reported more than USD 278.4 million in lymphedema product sales and rentals in 2025, representing 84% of its revenue.

 

Intermittent pneumatic compression (IPC) devices are FDA-cleared Class II medical systems that use inflatable sleeves to improve blood circulation and are primarily used for DVT prevention, lymphedema, and edema management in both hospital and home settings. The FDA-approved landscape includes widely used 510(k)-cleared systems such as Aircast VenaFlow and Bio Compression devices, along with advanced multi-chamber gradient pumps regulated under 21 CFR 870.5800 that require physician prescription. Innovation in the space is increasingly focused on home-use portability, wearable and tubeless designs, and expanded indications such as peripheral arterial disease, with devices like AIROS Medical’s ARTAIRA introducing timed compression cycles to support blood flow. Emerging pipelines also include smart, app-connected systems, real-time adherence tracking, and remote monitoring integration, alongside hybrid wearable platforms like Koya Medical’s Dayspring that aim to improve patient compliance and extend therapy beyond clinical environments.

 

How Is Product Demand Shifting Toward Portable IPC Devices?

Portable IPC devices accounted for an estimated 58.0% of the market in 2025 and are projected to grow at a CAGR of 7.8% during 2026–2032. Their leading position is supported by the movement of compression therapy beyond fixed hospital beds into home care, ambulatory procedures, rehabilitation, and post-operative recovery.

Portable systems are particularly suited to patients who require compression after discharge or repeated therapy at home. Enovis' VenaGo, for example, is designed as a portable DVT-prevention device for post-operative patients, supporting compression beyond the traditional inpatient setting. Chronic lymphedema care adds another demand stream because treatment can continue for long periods and often takes place outside hospitals.

The expansion of compact recovery devices is also increasing exposure in sports and rehabilitation. Hyperice markets its Normatec dynamic air-compression systems across athletic recovery and therapeutic environments, extending pneumatic compression into a broader wellness and rehabilitation customer base.

 

Non-portable IPC devices represented an estimated 42.0% share in 2025 and are forecast to grow at a CAGR of 5.4%. Demand remains concentrated in hospitals, large clinics, surgical departments, and other settings where reusable pumps can serve multiple patients through dedicated compression garments.

Hospital fleet replacement supports continued revenue even as portable devices gain share. Cardinal Health launched its Kendall SCD SmartFlow Compression System in the U.S. in November 2024 for patients at risk of DVT and PE, while Arjo upgraded its Flowtron ACS900 hospital compression platform. Large installed fleets provide recurring opportunities through equipment upgrades, replacements, and patient-contact sleeves.

 

Which Applications Generate the Largest IPC Device Demand?

DVT prevention held the largest application share at an estimated 43.0% in 2025 and is projected to expand at a CAGR of 5.8%. The segment is supported by millions of surgical and hospital episodes in which clinicians assess thrombosis risk.

AHRQ recorded 13.5 million ambulatory surgery encounters at hospital-owned U.S. facilities in 2023, up 9% from 2022. CDC also notes that patients face particularly high VTE risk during or shortly after hospitalization and surgery. IPC therefore remains an established mechanical prevention option alongside pharmacologic prophylaxis.

The opportunity extends from traditional inpatient surgery into shorter-stay and ambulatory pathways. Portable compression allows DVT prevention to continue after discharge, increasing the commercial value of devices that follow patients through the broader surgical recovery period.

 

Lymphedema management accounted for an estimated 32.0% of market revenue in 2025 and is expected to record the fastest application CAGR of 8.7%. Unlike short-duration hospital prophylaxis, lymphedema creates recurring therapy demand over extended periods.

CMS covers pneumatic compression devices for qualifying home lymphedema treatment, creating a structured reimbursement pathway after conservative treatment requirements are met. Public utilization evidence confirms the commercial importance of this channel. The supplied Medicare analysis identified 36,837 fee-for-service beneficiaries receiving E0651 compressor purchases in 2021, alongside substantial utilization of associated segmented garments.

Tactile Medical's recent performance provides another demand signal. Its lymphedema products generated USD 278.4 million in 2025, compared with USD 259.4 million in 2024. Continued FDA activity, including the July 31, 2026 substantially equivalent decision for the Flexitouch Plus Advanced Pneumatic Compression System, also indicates ongoing product investment in this category.

 

Chronic venous insufficiency and varicose-vein-related applications represented an estimated 18.0% share in 2025 and are projected to grow at a CAGR of 6.4%.

The segment is commercially relevant among patients with persistent lower-extremity swelling and venous stasis ulcers. A U.S. wound-care assessment estimates 500,000–600,000 people have venous leg ulcers, creating a sizeable population requiring prolonged compression and wound management.

CMS covers home pneumatic compression for qualifying chronic venous insufficiency with venous stasis ulcers, connecting disease persistence directly with reimbursed device demand. FDA-cleared systems such as the AIROS 6P also include venous stasis ulcers and related venous conditions within their indications.

 

Sports and rehabilitation accounted for an estimated 7.0% share in 2025 and are forecast to grow at a CAGR of 5.6%. The segment remains smaller than clinical VTE and lymphedema applications but broadens the IPC market beyond disease-focused treatment.

Professional sports programs, physiotherapy facilities, recovery centers, and individual athletes increasingly use dynamic air compression as part of post-exercise and rehabilitation routines. Hyperice's Normatec portfolio demonstrates the development of this separate commercial channel, with products positioned around athletic recovery and therapeutic use.

 

Which End Users Control IPC Purchasing?

Hospitals and clinics held the largest end-user share at an estimated 48.0% in 2025 and are projected to grow at a CAGR of 5.8%. Surgical volumes, inpatient immobility, trauma, cancer treatment, and hospital thromboprophylaxis programs keep institutional demand high.

CDC reports that as many as 70% of healthcare-associated VTE cases may be preventable, while fewer than half of hospitalized patients receive appropriate prevention measures. This leaves room for improved preventive-care implementation while maintaining demand for mechanical compression systems. Hospitals also create recurring revenue from sleeves and other patient-contact components even when controllers remain in service for several years.

 

Homecare settings accounted for an estimated 31.0% share in 2025 and are expected to register the fastest end-user CAGR of 8.6%.

Growth comes primarily from lymphedema and chronic venous disease patients who need ongoing therapy rather than short inpatient treatment. CMS reimbursement and expanded insurer networks have helped create a commercial pathway for home device placement. Tactile Medical's results demonstrate the scale this model can achieve, with lymphedema products accounting for 84% of company revenue in 2025. Homecare also favors portable devices, strengthening the connection between the fastest-growing product category and the fastest-growing end-user setting.

 

Ambulatory surgical centers represented an estimated 14.0% of the market in 2025 and are projected to grow at a CAGR of 7.2%.

Growth in outpatient orthopedic and other surgical procedures is increasing the need for compression that can begin around the procedure and continue during recovery. AHRQ's latest national dataset reported 13.5 million hospital-owned ambulatory surgery encounters in 2023, demonstrating the scale of outpatient surgical activity supporting this channel. Portable IPC systems are particularly well matched to this shift because they allow patients to continue mechanical prophylaxis outside the surgical facility.

 

Sports rehabilitation centers accounted for an estimated 7.0% share in 2025 and are forecast to expand at a CAGR of 5.3%.

Demand comes from professional and recreational sports, physiotherapy practices, recovery studios, and rehabilitation facilities. The expansion of portable compression systems has lowered the dependence of this segment on large institutional equipment, allowing clinics and individual athletes to access dynamic compression outside hospital environments.

 

Which Regions Offer the Strongest Commercial Opportunity?

North America held the largest regional share at an estimated 40.0% in 2025 and is projected to grow at a CAGR of 6.2%. The region benefits from high surgical activity, structured hospital VTE-prevention programs, established DME reimbursement, specialist lymphedema care, and a strong base of IPC suppliers.

The U.S. alone records up to 900,000 VTE cases annually, while Medicare provides defined coverage pathways for qualifying home pneumatic compression. Recent launches from Cardinal Health, Tactile Medical, Enovis, and other suppliers reinforce North America's role as a major commercial and product-development market.

 

Europe represented an estimated 28.0% share in 2025 and is forecast to grow at a CAGR of 6.3%.

Demand is supported by developed surgical systems, aging populations, institutional VTE prevention, rehabilitation networks, and established compression therapy practices. Arjo's continued investment in its Flowtron platform illustrates active competition within European hospital compression. Its updated ACS900 consumes approximately 14% less energy than the previous version, which can matter for hospitals operating large device fleets.

 

Asia Pacific accounted for an estimated 23.0% of revenue in 2025 and is projected to record the fastest regional CAGR of 8.5%.

Expansion of hospital infrastructure, surgical capacity, rehabilitation services, and chronic disease management is increasing the addressable IPC population. The region also carries a meaningful lymphatic-disease burden in several countries. WHO reports that more than 15 million people had lymphoedema associated with lymphatic filariasis in its global baseline estimate, while at least 36 million remain affected by chronic manifestations of the disease worldwide.

Rising access to private healthcare and home-based therapy should gradually shift regional demand beyond institutional procurement toward portable and patient-managed compression.

 

Latin America represented an estimated 5.0% share in 2025 and is projected to grow at a CAGR of 7.1%.

Growth is being supported by expanding private hospital networks, orthopedic procedures, rehabilitation services, and wider availability of imported compression technologies. Hospital procurement remains more important than reimbursed home DME in many markets, creating opportunities for suppliers with strong distributor relationships.

 

The Middle East & Africa accounted for an estimated 4.0% share in 2025 and are forecast to grow at a CAGR of 7.4%.

Gulf healthcare investment supports adoption of modern surgical and rehabilitation equipment, while parts of Africa carry significant chronic lymphatic disease burdens. Access remains uneven, making hospital procurement, public-health infrastructure, specialist clinics, and distributor coverage important determinants of commercial expansion.

 

How Are Reimbursement and Care Delivery Reshaping Market Growth?

Reimbursement is one of the strongest differences between hospital IPC and home pneumatic compression. Hospitals typically procure devices through institutional budgets and use them according to thromboprophylaxis protocols, while home therapy depends on clinician documentation, payer approval, coverage rules, and supplier reimbursement capabilities.

CMS coverage establishes a defined pathway for lymphedema and chronic venous insufficiency with venous stasis ulcers. This favors suppliers that can manage prescriptions, insurance authorization, documentation, and patient onboarding in addition to supplying hardware.

The business model is consequently extending beyond pumps. Tactile Medical's home-compression operations demonstrate how manufacturers can build revenue around device placement, garments, rentals, patient support, and payer relationships. The company's recent FDA activity further shows continued investment in advanced pneumatic compression.

 

How Is Competition Evolving in the IPC Devices Market?

Cardinal Health: Hospital-Focused Leader in DVT & PE Prevention with Kendall SCD SmartFlow Expansion

Cardinal Health maintains a strong hospital-focused position through its Kendall SCD portfolio. The November 2024 U.S. launch of Kendall SCD SmartFlow expands its offering for DVT and PE prevention and builds on an established hospital compression franchise.

 

Tactile Medical: Fast-Growing Leader in Home Lymphedema Compression Therapy Market

Tactile Medical is strongly positioned in home lymphedema compression. Its USD 278.4 million in 2025 lymphedema sales and rental revenue, continuing development of the Nimbl platform, and July 2026 Flexitouch Plus FDA decision demonstrate sustained investment in chronic home therapy.

 

Arjo: Strengthening Hospital VTE Prevention Portfolio with Energy-Efficient Flowtron ACS900

Arjo competes primarily through hospital-based VTE prevention with its Flowtron portfolio. The ACS900 upgrade combines clinical compression with lower operating energy requirements, supporting procurement discussions around both patient care and hospital fleet economics.

 

Enovis: Expanding Portable IPC Solutions for Ambulatory Surgery and Post-Discharge DVT Prevention

Enovis participates in both hospital and post-operative compression through VenaFlow and portable VenaGo systems. Its portable strategy is well aligned with ambulatory procedures and post-discharge DVT prevention, where compression increasingly follows the patient beyond the hospital.

 

AIROS Medical & Lympha Press: Advancing Sequential Compression Therapy for Lymphedema and Venous Disorders

AIROS Medical competes in sequential pneumatic compression for lymphedema, chronic edema, venous insufficiency, and venous stasis ulcers. FDA clearance for its AIROS 6P supports its position across home and clinical compression therapy. Mego Afek's Lympha Press portfolio adds further competition in the chronic lymphedema segment.

 

Competition in the Global Intermittent Pneumatic Compression Devices Market is increasingly divided between hospital-focused suppliers and companies building specialized home-care and lymphedema businesses. Hospital suppliers benefit from surgical volumes, equipment replacement, institutional contracts, and recurring garment consumption, while home-care companies compete through payer access, clinical referrals, portable devices, patient support, and longer-duration therapy. The combination of established VTE-prevention demand and faster growth in home lymphedema care, portable systems, ambulatory surgery, and Asia Pacific is expected to reshape the market's revenue mix through 2032.

 

Intermittent Pneumatic Compression Devices Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.1 Billion
Revenue Forecast in 2032	USD 6.1 Billion
Overall Growth Rate	CAGR of 6.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Portable IPC Devices, Non-portable IPC Devices
By Application	DVT Prevention, Lymphedema Management, Chronic Venous Insufficiency and Varicose-Vein-Related Applications, Sports and Rehabilitation
By End User	Hospitals & Clinics, Homecare Settings, Ambulatory Surgical Centers, Sports Rehabilitation Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising need for mechanical VTE prevention across surgical and hospitalized patients, expanding home-based lymphedema and chronic venous disease management, growing adoption of portable IPC devices for post-discharge and ambulatory care, supportive reimbursement pathways for qualifying home pneumatic compression therapy
Customization Option	Available upon request